289 related articles for article (PubMed ID: 12161471)
1. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
[TBL] [Abstract][Full Text] [Related]
2. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
3. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
[TBL] [Abstract][Full Text] [Related]
5. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
6. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
7. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
8. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
9. [Acromegaly].
Chanson P
Presse Med; 2009 Jan; 38(1):92-102. PubMed ID: 19004612
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.
Jane JA; Starke RM; Elzoghby MA; Reames DL; Payne SC; Thorner MO; Marshall JC; Laws ER; Vance ML
J Clin Endocrinol Metab; 2011 Sep; 96(9):2732-40. PubMed ID: 21715544
[TBL] [Abstract][Full Text] [Related]
11. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index.
Arafat AM; Möhlig M; Weickert MO; Perschel FH; Purschwitz J; Spranger J; Strasburger CJ; Schöfl C; Pfeiffer AF
J Clin Endocrinol Metab; 2008 Apr; 93(4):1254-62. PubMed ID: 18171702
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL
J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
[TBL] [Abstract][Full Text] [Related]
14. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
15. GH response to oral glucose tolerance test: a comparison between patients with acromegaly and other pituitary disorders.
Verrua E; Filopanti M; Ronchi CL; Olgiati L; Ferrante E; Giavoli C; Sala E; Mantovani G; Arosio M; Beck-Peccoz P; Lania AG; Spada A
J Clin Endocrinol Metab; 2011 Jan; 96(1):E83-8. PubMed ID: 20962023
[TBL] [Abstract][Full Text] [Related]
16. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.
Kinoshita Y; Tominaga A; Usui S; Arita K; Sakoguchi T; Sugiyama K; Kurisu K
Neurosurg Rev; 2016 Apr; 39(2):313-8; discussion 318-9. PubMed ID: 26785642
[TBL] [Abstract][Full Text] [Related]
18. Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result?
Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Feb; 59(1):54-8. PubMed ID: 25926115
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of acromegaly: state of the art.
Kannan S; Kennedy L
Expert Opin Med Diagn; 2013 Sep; 7(5):443-53. PubMed ID: 23971897
[TBL] [Abstract][Full Text] [Related]
20. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
